Fulcrum Therapeutics

Forecast & Rating7 analysts currently cover Fulcrum Therapeutics, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $3.40, about 8.6% downside from the current price of $3.72. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 47.5% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Fulcrum Therapeutics's outlook. Data as of Aug 7, 2026; for reference only and not investment advice.